
ARKADY NISMAN, PHARMD
Advertisement
Articles by ARKADY NISMAN, PHARMD



Given the relatively static rate of seizure freedom with the current antiepileptic drug (AED) armamentarium, a need remains for the development of new compounds to help enable more patients achieve seizure freedom. Fortunately, several investigational therapeutic agents and delivery systems are in phase 3 development, which are being investigated for the treatment of orphan diseases and focal-onset and generalized-onset seizures.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
2
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
3
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5
